Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
Vanguard Health Care ETF (VHT) Eyes a Move to $360 With Roughly +10% Upside

Vanguard Health Care ETF (VHT) Eyes a Move to $360 With Roughly +10% Upside

Key Takeaways

  • The Vanguard Health Care ETF (VHT) recently traded near $327, just below its 52-week high of roughly $332, so a move to $360 would require an advance of about 10%.
  • Because VHT is an exchange-traded fund (ETF), no single sell-side analyst issues a direct price target for it; the $360 objective reflects public discussion and technical context rather than an analyst consensus.
  • As context, the holdings-weighted average 12-month target across the roughly 400 stocks VHT owns sits near $339, with a broad low-to-high range of about $276 to $407, according to TipRanks.
  • The strongest supports are healthcare's defensive demand, innovation in GLP-1 and oncology drugs, and expectations that sector earnings growth could reaccelerate after a soft patch.
  • The biggest risks include a pending pharmaceutical "patent cliff," historically elevated valuations, and concentration in top holdings such as Eli Lilly.
  • Readers can follow VHT's Major News, Today's Price Move, Forecast, and Earnings on Tickeron's dedicated pages to track developments affecting the fund.
  • Explore Trending AI Robots to see how AI-driven strategies are scanning the market for opportunities.

How the $360 Target Came Into View

VHT is the Vanguard Health Care ETF, a fund that tracks the MSCI U.S. Investable Market Health Care 25/50 Index, holding about 405 U.S. healthcare companies spanning pharmaceuticals, biotechnology, medical devices, and health insurers. As an ETF, it does not receive standalone analyst price targets the way an individual stock does. The $360 figure used here is a fallback objective drawn from public discussion and technical context: it sits roughly 10% above the fund's recent price, just beyond its all-time high, and aligns with the upper end of publicly discussed healthcare outlooks. It should not be read as a published consensus.

For perspective, TipRanks computes a holdings-weighted 12-month forecast of about $339.45 based on analyst targets across 424 stocks held in the fund, with a range from roughly $276 to $407. A separate view from financial media citing Wall Street estimates has pointed to a roughly 21% total return for the healthcare sector over the coming year. The $360 milestone therefore represents a reasonable, publicly grounded level—not a guarantee. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

Current Market Position and Path Toward the Target

VHT recently changed hands around $327, near the top of its 52-week range of approximately $265 to $332. Reaching $360 would require a gain of about 10%, which is best described as a modest move for a diversified sector fund. Notably, the fund has already recovered sharply from its 52-week low, so the path to $360 would require breaking decisively to a new all-time high and then sustaining that momentum.

The realistic route would depend on continued earnings growth from mega-cap holdings such as Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), and UnitedHealth Group (UNH), which together represent a meaningful share of the portfolio. A rotation back into defensive, dividend-paying sectors would also help, as would multiple expansion if interest rates ease.

What Could Support a Move Toward the Target

  • Defensive demand: Healthcare spending tends to hold up across economic cycles, supporting the sector's relative stability.
  • Innovation pipeline: GLP-1 weight-loss drugs, oncology treatments, and medical devices continue to drive revenue growth at leading holdings.
  • Earnings reacceleration: Wall Street estimates cited by media sources point to slower healthcare EPS (earnings per share) growth near 3% in 2026 before accelerating toward 19% in 2027.
  • Falling rates: Lower yields can support valuations for longer-duration, cash-flow-rich healthcare names and make the fund's roughly 1.4% dividend yield more competitive.
  • Low cost: VHT's 0.09% expense ratio keeps investor returns close to the underlying index.

What Could Prevent the Target From Being Reached

  • Patent cliff: Industry research cited in financial media notes that nearly 200 drugs—including 69 generating at least $1 billion in annual sales—could lose patent protection within a few years, pressuring revenue.
  • Valuation: The healthcare sector trades near 27 times earnings, which some commentators describe as expensive relative to its growth.
  • Policy and regulatory risk: Drug-pricing reform and shifting reimbursement rules remain recurring overhangs.
  • Concentration: A handful of large names drive returns, so weakness in a single mega-cap holding can weigh heavily on the fund.
  • Historical underperformance: Over the past decade VHT has lagged the broader S&P 500, and sector rotation away from defensive names could stall momentum.

Technical Levels and Market Structure

VHT's most important structural level is its all-time high near $331–$332, which also acts as near-term resistance. A decisive breakout above that zone would put the fund in uncharted territory and make the $360 psychological level the next natural milestone to watch. On the downside, support sits near the recent consolidation zone around $310–$315, with the 52-week low near $265 serving as the broader floor. The fund's long-term trend remains upward, having rebounded strongly from its 52-week low. From what I see, monitoring these levels closely helps frame realistic expectations.

Time Horizon and What Investors Should Monitor

Holdings-weighted analyst targets typically reflect a roughly 12-month research horizon, though individual estimates vary widely. Investors tracking the path toward $360 should watch quarterly earnings from the fund's largest holdings, any guidance revisions across pharma and managed care, Federal Reserve rate decisions, and changes in healthcare policy. For an ETF, fund flows and rebalancing of the underlying index can also influence performance over time. I'm watching this closely as part of broader sector analysis.

Final Assessment

The $360 objective for VHT is a publicly grounded, technically informed milestone rather than an analyst consensus. It implies a roughly 10% advance from the fund's recent price near $327—a modest move that would require a decisive breakout to a new all-time high. Support could come from defensive demand, a reacceleration in sector earnings, and falling interest rates, while the patent cliff, elevated valuations, and policy risk are the principal obstacles. The wide spread between the holdings-weighted analyst range near $276 and $407 underscores genuine disagreement about the sector's outlook. Investors should monitor mega-cap earnings, rate policy, and fund flows rather than treat any single level as a foregone conclusion.

AI Daily Buy/Sell Signals

In my own research process, Tickeron's AI Daily Buy/Sell Signals have become a useful complement when evaluating sector ETFs like VHT. These tools apply artificial intelligence to monitor thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For an index fund such as this one, they can help identify shifts in momentum, potential entry or exit points, and overall trend changes more efficiently than manual review alone. I find this data-driven layer adds helpful context alongside traditional fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VHT

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


VHT in -2.29% downward trend, falling for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VHT declined for three days, in 243 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for VHT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VHT as a result. In 64 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for VHT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

VHT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 254 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

VHT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 200 of 251 cases where VHT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to track the performance of the MSCI U.S. Investable Market Index (IMI)/Health Care 25/50. The fund employs an indexing investment approach designed to track the performance of the index, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the GICS. The Advisor attempts to replicate the target index by seeking to invest all, or substantially all, of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.

Market Cap

The average market capitalization across the Vanguard Health Care ETF (VHT) ETF is 25.9B. The market cap for tickers in the group ranges from 15.62M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is ACH at 15.62M.

High and low price notable news

The average weekly price growth across all stocks in the Vanguard Health Care ETF (VHT) ETF was -6%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 18%. SLS experienced the highest price growth at 74%, while UPB experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Vanguard Health Care ETF (VHT) ETF was 35%. For the same stocks of the ETF, the average monthly volume growth was 20% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 50
Price Growth Rating: 54
SMR Rating: 80
Profit Risk Rating: 82
Seasonality Score: 13 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.